CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

fluticasone furoate/vilanterol

Last Updated: June 17, 2020
Result type: Reports
Project Number: SR0568-000
Product Line: Reimbursement Review

Generic Name: fluticasone furoate/vilanterol

Brand Name: Breo Ellipta

Manufacturer: GlaxoSmithKline Inc.

Therapeutic Area: Asthma

Indications: Asthma

Manufacturer Requested Reimbursement Criteria1: Breo Ellipta should be reimbursed preferentially to Advair to maximize asthma control in patients aged 18 years and older with reversible obstructive airways disease.

Submission Type: Resubmission

Project Status: Withdrawn

Biosimilar: No

Fee Schedule: Schedule B

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedApril 04, 2018
Patient group input closedMay 24, 2018

- No patient input submission received

Submission receivedMay 02, 2018
Submission acceptedMay 16, 2018
Review initiatedMay 17, 2018
Draft CADTH review report(s) sent to sponsorAugust 01, 2018
Comments from sponsor on draft CADTH review report(s) receivedAugust 13, 2018
Redaction requests from sponsor on draft CADTH review report(s) receivedAugust 15, 2018

- Voluntarily withdrawn by the manufacturer on 2018-08-14